[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Nossa Senhora da Conceicao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":152},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,73,100,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100625715","phase-4-effect-of-the-addition-of-adenosine-on-myocardial-protection-during-cardiopulmonary-bypass-100625715",false,"NCT07426237","Effect of the Addition of Adenosine on Myocardial Protection During Cardiopulmonary Bypass","Effect of the Addition of Adenosine on Myocardial Protection During Cardiopulmonary Bypass: A Double-Blind Randomized Clinical Trial","ADENOCARDIO","Inclusion Criteria:\n\n* All patients aged 18 years or older undergoing elective isolated valve replacement or coronary artery bypass grafting with cardiopulmonary bypass at Hospital Nossa Senhora da Conceição, Porto Alegre\n\nExclusion Criteria:\n\n* Previous cardiac surgery;\n* Chronic kidney disease (serum creatinine greater than 2.0 mg\u002FdL);\n* Severe psychiatric illness;\n* Urgent or emergency surgery;\n* Multiple cardiac procedures.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to evaluate whether the addition of adenosine to standard cardioplegia improves myocardial protection in adult patients undergoing on-pump cardiac surgery. The study population includes adult patients of both sexes undergoing elective cardiac procedures requiring cardiopulmonary bypass and cardioplegic arrest.\n\nThe main questions this trial aims to answer are:\n\nDoes the addition of adenosine to cardioplegia affect myocardial protection as assessed by transesophageal echocardiography (TEE)?\n\nWhat is the effect of adenosine on biochemical markers of myocardial injury, such as postoperative high-sensitivity troponin levels?\n\nWhat is the effect of adenosine on perioperative hemodynamic support requirements, as quantified by the Vasoactive-Inotropic Score (VIS)?\n\nResearchers will compare patients receiving adenosine-supplemented cardioplegia with those receiving standard cardioplegia (placebo) to assess differences in echocardiographic indicators of myocardial protection, biomarker release, and need for vasoactive\u002Finotropic support.\n\nParticipants will:\n\nReceive either adenosine-supplemented cardioplegia (adenosine 1.2 mmol\u002FL; 24 mg) or placebo according to randomization.\n\nUndergo standard perioperative monitoring during cardiac surgery.\n\nUndergo intraoperative transesophageal echocardiography (TEE) to evaluate myocardial protection by comparing pre- and post-cardiopulmonary bypass (CPB) measurements.\n\nHave postoperative laboratory testing for high-sensitivity troponin at baseline, 2h, 12h, and 24h after clamp release.\n\nHave hemodynamic support requirements recorded and VIS calculated at the end of surgery and at 12h and 24h postoperatively.\n\nBe followed for perioperative clinical outcomes including arrhythmias, need for cardioversion or mechanical circulatory support, ICU\u002Fhospital length of stay, myocardial infarction, and mortality.",[27],"Myocardial Protection",[29,30,31],"myocardial protection","cardioplegia","del Nido","NOT_YET_RECRUITING","2026-02-19",{"date":35,"type":36},"2026-02-23","ACTUAL",{"date":38,"type":21},"2026-03-30",{"date":40,"type":21},"2027-07-01",{"name":42,"class":43},"Hospital Nossa Senhora da Conceicao","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100598159","phase-3-weaning-approaches-for-vasopressin-in-sepsis-100598159","NCT07067866","Weaning Approaches for Vasopressin in Sepsis","Weaning Approaches for Vasopressin in Sepsis - a Randomized Controlled Trial of Titrated Versus Abrupt Discontinuation During Stabilization of Septic Shock - WAVES Trial","WAVES","Inclusion Criteria:\n\n* Age over 18 years\n* Admitted to the Intensive Care Unit\n* Patients with vasopressor dependent sepsis\n* Receiving combined norepinephrine and vasopressin therapy\n\nExclusion Criteria:\n\n* Withdrawal\u002Freduction of vasopressin related to a plan of treatment limitation or palliative care\n* Withdrawal\u002Freduction of vasopressin associated with the initiation of adrenaline or any other vasopressor",{"count":54,"type":21},82,[56],"PHASE3","In this study, we aim to evaluate the incidence of hypotension during vasopressin weaning by comparing two methods - titrated reduction versus abrupt withdrawal - through the conduct of a randomized clinical trial.",[59],"Septic Shock",[61,62,63],"vasopressin","septic shock","vasopressor weaning","RECRUITING","2025-12-29",{"date":67,"type":36},"2026-01-02",{"date":69,"type":36},"2025-10-01",{"date":71,"type":21},"2028-10-01",{"name":42,"class":43},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100615287","prospective-validation-of-an-artificial-intelligence-tool-for-pre-anesthetic-assessment-100615287","NCT07290647","Prospective Validation of an Artificial Intelligence Tool for Pre-Anesthetic Assessment","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Patients scheduled for elective non-cardiac surgeries\n\nExclusion Criteria:\n\n* Patients undergoing diagnostic procedures with isolated sedation or local anesthesia\n* If a patient undergoes more than one surgical intervention during the same hospitalization, only the major procedure will be considered (i.e., additional procedures during the same admission are not eligible for separate inclusion).",{"count":80,"type":21},270,"OBSERVATIONAL","This prospective observational cohort study aims to validate an artificial intelligence (AI) tool designed for pre-anesthetic assessment in Portuguese, tailored to the Brazilian healthcare context. Conducted at a single tertiary hospital, the study will enroll 270 adult patients (aged \\>18 years) scheduled for elective non-cardiac surgeries. Participants will use the AI tool to complete a self-assessment, generating general patient guidance and a detailed medical evaluation (the latter withheld from the anesthesiologist). A standard pre-anesthetic evaluation will then be performed by an anesthesiologist blinded to the AI results. A third blinded anesthesiologist will compare the assessments for accuracy, consistency, and risk identification (e.g., ASA classification and perioperative risk models). Primary outcome is concordance between AI and human assessments using Cohen's Kappa. Secondary outcomes include anesthesiologist perceptions of the tool's utility, impact on assessment quality, and patient usability challenges. The study poses minimal risks, with data collected over 24 months, and aims to enhance perioperative safety and efficiency in Brazil.",[84],"Preoperative Care",[86,87,88,89,90,91],"Artificial Intelligence","Large Language Model","Preoperative Evaluation","Perioperative Care","Risk Assessment","Observational Study","2025-12-05",{"date":94,"type":36},"2025-12-18",{"date":96,"type":21},"2026-03-01",{"date":98,"type":21},"2028-06-30",{"name":42,"class":43},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":44},"100547201","ariscat-asa-and-las-vegas-risk-scores-and-the-incidence-of-postoperative-pulmonary-complications-in-thoracic-surgery-100547201","NCT06404892","ARISCAT, ASA and LAS VEGAS Risk Scores and the Incidence of Postoperative Pulmonary Complications in Thoracic Surgery","ARISCAT, ASA and LAS VEGAS Risk Scores and the Incidence of Postoperative Pulmonary Complications in Patients Undergoing Thoracic Surgery With Single-lung Ventilation","Inclusion Criteria:\n\n* Adult patients undergoing any thoracic procedure associated with intraoperative single-lung ventilation.\n\nExclusion Criteria:\n\n* Patients undergoing cardiac surgery, pregnant women, patient refusal, contraindications to proposed surgical, anesthetic or analgesic techniques, sepsis, psychiatric illness, uncontrolled endocrine, kidney or liver disease and coagulopathies.",{"count":108,"type":21},110,"Postoperative pulmonary complications (PPC) are among the main complications after the anesthetic-surgical procedure. It can be said that thoracic surgery results in impaired respiratory function in the postoperatively, due to the decrease in lung volumes and capacities (the vital capacity decreases by approximately 50-60% and functional residual capacity decreases by approximately 30% in the first 24 hours after surgery) diaphragm dysfunction, gas exchange impaired, cough and ineffective mucociliary clearance. Thus, our hypothesis is that the application of preoperative risk scores normally used for non-cardiac and non-thoracic surgeries may be effective on the predictability of the occurrence of CPP in patients undergoing ventilation single-lung. This is a prospective observational study in order to evaluate the performance of the ASA, ARISCAT and LAS VEGAS risk scores for predict the occurrence of postoperative pulmonary complications (PPC) in patients undergoing thoracic surgery with single-lung ventilation.",[111],"Postoperative Complications",[113,114,115,116],"postoperative pumonary complications","ARISCAT score","LAS VEGAS score","ASA score","2025-05-03",{"date":119,"type":36},"2025-05-06",{"date":121,"type":36},"2024-07-01",{"date":123,"type":21},"2025-12-31",{"name":42,"class":43},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100551910","complications-associated-with-multiple-central-venous-accesses-in-the-internal-jugular-vein-100551910","NCT06466226","Complications Associated With Multiple Central Venous Accesses in the Internal Jugular Vein","Incidence of Complications Associated With Multiple Central Venous Accesses in the Internal Jugular Vein: a Randomized Multicenter Non-inferiority Clinical Trial","Inclusion Criteria:\n\n* Patients with preanesthetic planning for insertion of at least two central venous catheters.\n* Adult ASA I to IV patients (over 18 years old), scheduled to undergo cardiac surgeries, vascular surgeries, major abdominal or thoracic surgeries, liver transplants and lung transplants.\n\nExclusion Criteria:\n\n* Patients with a previous history of central venous thrombosis or central venous stenosis will be excluded from the research protocol.\n* Patients without preanesthetic planning insertion of at least two central venous catheters.",{"count":133,"type":21},156,[135],"NA","Patients at risk of significant intraoperative blood loss and\u002For potential hemodynamic instability often necessitate the placement of two or more central venous catheters, including large bore catheters. In tertiary hospitals, anesthesiologists frequently encounter patients undergoing major surgeries such as liver transplantation, lung transplantation, cardiac surgery, and vascular surgery, who require multiple central venous punctures as part of routine anesthetic management. However, most review and consensus articles do not directly address the utilization of multiple catheters in the same venous site, nor establish formal recommendations regarding this practice. The latest consensus on central venous access from the American Association of Anesthesiologists (ASA), published in 2012, briefly touches upon some aspects related to this practice but does not outline any contraindications. Thus, the investigators have identified a gap in evidence and robust prospective studies addressing the use of more than one catheter in the same site for central venous access. This lacuna underscores the importance of conducting a controlled clinical study in our institutions to establish the efficacy and safety of this approach in the perioperative context. The present study aims to evaluate the incidence of mechanical complications (such as dysrhythmias, arterial puncture, hematoma, pneumothorax\u002Fhemothorax, insertion failure, or inadequate positioning) within the first 24 hours after double puncture of the internal jugular vein compared to puncture of two distinct central vessels, in patients undergoing multiple central venous accesses during major surgeries. This study will be designed as a prospective, randomized, non-inferiority, open, parallel clinical trial with two groups for patient allocation. Patients identified for multiple central venous accesses as part of preoperative anesthetic planning will be randomly allocated to either receive two central venous accesses in two separate sites (Group I or control group) or two concurrent central venous accesses in a single internal jugular vein (Group II or intervention group). Only adult patients classified as ASA I to IV (over 18 years old), scheduled for major surgery, will be eligible for inclusion.",[138,139,140],"Central Venous Catheters","Catheter Complications","Catheter Related Complication",[142,143,144],"central venous access","complications","major surgery","2024-06-17",{"date":147,"type":36},"2024-06-20",{"date":121,"type":21},{"date":150,"type":21},"2027-12-31",{"name":42,"class":43},""]